Intervention
toxicity
The participants in the experimental group received envonalkib 600 mg BID, and the control group received crizotinib 250 mg BID in each 28-day cycle. In case of toxicity during the study, dose adjustment was considered to 500 mg BID and 400 mg BID in the envonalkib group and to 200 mg BID and 250 mg QD in the crizotinib group. In case that a third dose reduction was needed, the treatment was discontinued. Once the dose was reduced, it could not be increased again.